Erdera - Translational Research Services

ERDERA’s Public-Private Collaboration Accelerator (PPCA)

Bridging the gap between scientific discovery and investment-ready innovation with high potential to significantly improve the lives of patients with rare diseases and their communities.

The ERDERA Public-Private Collaboration Accelerator (PPCA) is both a translational and public-private collaboration accelerator for rare diseases. Its aim is to bring projects to an investment-ready stage by providing advice and expertise in drug development and facilitating collaboration with key and relevant public and private stakeholders.

The accelerator will leverage the significant European rare disease R&D ecosystem orchestrated under ERDERA as well as its predecessor EJPRD, and build targeted networks for supporting non-clinical development of promising early-stage projects, addressing patient therapeutic unmet needs.

What are the goals of the Accelerator?

➩ To secure a path to clinical implementation of promising drugs and therapies for rare diseases patients.

➩ To support the development of research projects from early-stage to investment-ready stage.

➩ To support 5 to 10 new projects per year over the next seven years.

What charaterises the Accelerator?

➩ It is dedicated exclusively to rare diseases, and has a strong patient-centred approach.

➩ It benefits from the ERDERA consortium ecosystem, which includes many complementary resources and expertise and a multidisciplinary team.

➩ It is open to early stage projects.

➩ Its service is free for the beneficiaries.

➩ There is no ERDERA co-ownership of results and intellectual property.

The 4 Ds of the Accelerator process

DETECT

Actively sourcing innovative projects from ERDERA and external networks.

A focus is put on identifying ideas with a strong translational potential and mapping them to the right investors at an early stage.

DECIDE

Once potential projects are detected, their scientific rationale, unmet medical needs, and overall feasibility are thoroughly evaluated.

This rigorous selection ensures that only investor-oriented and high-impact programs move forward.

DESIGN

Once selected, ERDERA provides a range of support services and work with towards securing resources for key preclinical studies.

These resources help teams refine their strategies and become fully investor-ready.

DEVELOP

Finally, projects are advanced by connecting them with potential funders and investors, identified through targeted searches and roadshows.

This sets the stage for successful clinical development.

Reach out to ERDERA!

If you are a researcher, and

  • You are working on rare disease translational projects.
  • You have identified a therapeutic solution, a target and you are eager to advance your research to the next stage, transforming it into a tangible result that can be scaled up for wider impact.
  • You are motivated to explore collaborative approaches.

A member of the Acceleration Hub team will review your submission and be in touch to discuss the next steps. We look forward to discovering how we can help accelerate your initiative and bring life-changing solutions to rare disease patients.

Tell us how we can help you accelerate your goals in Rare Diseases

Please only share non-confidential information, and if you are unsure about disclosure, we invite you to check with your TTO first.

Be sure to include the disease context, key scientific questions, how your solution addresses patient needs, and your current stage of development.

Consent *

The information of this form will be used for this purpose only and may be shared with the relevant parties of the Public-Private Collaborative Accelerator members, ERDERA consortium, and external experts. The title and abstract of this proposal, and names of the consortium members may also be shared publicly in ERDERA website. The information you should provide includes personal data referring to contact details, such as your name, email address and phone number. Personal data will be collected to allow contact for further details, if needed. No sensitive data will be collected. All the collected data will be kept confidential and will not circulate beyond the ERDERA consortium prior to your specific notification and authorization. All the information will be made available in an aggregated manner (e.g. cumulative data and statistics). The Public-Private Collaborative Accelerator members will be responsible for the collection and processing of personal data (see Privacy policy).

I have read the above information and I authorise the processing of project and personal data, in compliance with the European General Data Protection Regulation, Reg (EU) 2016/679 for the specific purpose they are collected (any communication of personal data to private or public subject will be allowed only for the specific purpose they are collected).

I authorise the collection, storage and use of my project and personal data to be used by the ERDERA Public-Private Collaborative Accelerator program.

I authorise the collection, storage and use of my personal data to be contacted by the ERDERA services program.

I authorise to be contacted for involvement in future collaborative initiatives, which might fall within the scope of my research activity.

I authorise to be contacted for dissemination and communication activities (e.g. newsletters, invitations to meetings).

Share this page